Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.

[1]  J. Lifson,et al.  HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism. , 2008, The Journal of clinical investigation.

[2]  G. Peters,et al.  Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. , 2008, Blood.

[3]  B. Blanco,et al.  The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes , 2008, Haematologica.

[4]  M. Gilliet,et al.  Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases , 2008, Nature Reviews Immunology.

[5]  C. Liu,et al.  Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. , 2008, The Journal of clinical investigation.

[6]  D. Dingli,et al.  Improved survival in multiple myeloma and the impact of novel therapies. , 2008, Blood.

[7]  H. Brenner,et al.  Recent major improvement in long-term survival of younger patients with multiple myeloma. , 2008, Blood.

[8]  W. Dougall,et al.  RANK ligand as a therapeutic target for bone metastases and multiple myeloma. , 2008, Cancer treatment reviews.

[9]  N. Munshi,et al.  Neutralizing B-Cell–Activating Factor Antibody Improves Survival and Inhibits Osteoclastogenesis in a Severe Combined Immunodeficient Human Multiple Myeloma Model , 2007, Clinical Cancer Research.

[10]  Kenneth C. Anderson,et al.  Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets , 2007, Nature Reviews Cancer.

[11]  A. Krieg.  TLR9 and DNA 'feel' RAGE , 2007, Nature Immunology.

[12]  Kenneth C Anderson,et al.  Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. , 2007, Experimental hematology.

[13]  S. Jagannath,et al.  Bortezomib disrupts tumour–dendritic cell interactions in myeloma and lymphoma: therapeutic implications , 2007, British journal of haematology.

[14]  W. Dalton,et al.  Synopsis of a Roundtable on Validating Novel Therapeutics for Multiple Myeloma , 2006, Clinical Cancer Research.

[15]  R. Steinman,et al.  Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. , 2006, Blood.

[16]  M. Herling,et al.  Expression of the plasmacytoid dendritic cell marker BDCA-2 supports a spectrum of maturation among CD4+ CD56+ hematodermic neoplasms , 2006, Modern Pathology.

[17]  S. Jagannath,et al.  Enhancement of clonogenicity of human multiple myeloma by dendritic cells , 2006, The Journal of experimental medicine.

[18]  D. Ribatti,et al.  Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma , 2006, Oncogene.

[19]  H. Johnsen,et al.  Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma , 2006, Clinical and experimental immunology.

[20]  G. Blackburn,et al.  Soy phytochemicals prevent orthotopic growth and metastasis of bladder cancer in mice by alterations of cancer cell proliferation and apoptosis and tumor angiogenesis. , 2006, Cancer research.

[21]  Hiroshi Yasui,et al.  A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. , 2005, Cancer cell.

[22]  S. Akira,et al.  Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus , 2005, The Journal of experimental medicine.

[23]  P. L. Bergsagel,et al.  Molecular pathogenesis and a consequent classification of multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Vollmer.  Progress in drug development of immunostimulatory CpG oligodeoxynucleotide ligands for TLR9 , 2005, Expert opinion on biological therapy.

[25]  Weiping Zou,et al.  Immunosuppressive networks in the tumour environment and their therapeutic relevance , 2005, Nature Reviews Cancer.

[26]  N. Bhardwaj,et al.  Plasmacytoid Dendritic Cells: Linking Innate and Adaptive Immunity , 2005, Journal of Virology.

[27]  G. Trinchieri,et al.  Plasmacytoid dendritic cells in immunity , 2004, Nature Immunology.

[28]  Pierfrancesco Tassone,et al.  A clinically relevant SCID-hu in vivo model of human multiple myeloma. , 2004, Blood.

[29]  Angela Panoskaltsis-Mortari,et al.  Human Plasmacytoid Dendritic Cells Activated by CpG Oligodeoxynucleotides Induce the Generation of CD4+CD25+ Regulatory T Cells1 , 2004, The Journal of Immunology.

[30]  T. Giese,et al.  Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help. , 2004, Blood.

[31]  N. Callander,et al.  And Growth of Myeloma Cells Il-3 Expression by Myeloma Cells Increases Both Osteoclast Formation , 2022 .

[32]  P. Richardson,et al.  Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. , 2003, Blood.

[33]  Virginia Pascual,et al.  Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. , 2003, Immunity.

[34]  K. Okawa,et al.  Plasmacytoid dendritic cells: from specific surface markers to specific cellular functions. , 2002, Human immunology.

[35]  I. Maclennan,et al.  Dendritic cells, BAFF, and APRIL: innate players in adaptive antibody responses. , 2002, Immunity.

[36]  M. Baccarani,et al.  Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. , 2002, Blood.

[37]  M. Gilliet,et al.  Generation of Human CD8 T Regulatory Cells by CD40 Ligand–activated Plasmacytoid Dendritic Cells , 2002, The Journal of experimental medicine.

[38]  Antonio Lanzavecchia,et al.  BDCA-2, a Novel Plasmacytoid Dendritic Cell–specific Type II C-type Lectin, Mediates Antigen Capture and Is a Potent Inhibitor of Interferon α/β Induction , 2001, The Journal of experimental medicine.

[39]  T. Curiel,et al.  Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells , 2001, Nature Medicine.

[40]  D. Joshua,et al.  Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. , 2001, Blood.

[41]  I. Maclennan,et al.  Dendritic cells associated with plasmablast survival , 1999, European journal of immunology.

[42]  N. Kadowaki,et al.  The nature of the principal type 1 interferon-producing cells in human blood. , 1999, Science.

[43]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[44]  J. Banchereau,et al.  The Enigmatic Plasmacytoid T Cells Develop into Dendritic Cells with Interleukin (IL)-3 and CD40-Ligand , 1997, The Journal of experimental medicine.

[45]  T. Libermann,et al.  Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. , 1996, Blood.

[46]  R. Steinman,et al.  Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. , 1994, Immunology.

[47]  R. Steinman,et al.  IDENTIFICATION OF A NOVEL CELL TYPE IN PERIPHERAL LYMPHOID ORGANS OF MICE , 1974, The Journal of experimental medicine.

[48]  R. Steinman,et al.  Identification of a novel cell type in peripheral lymphoid organs of mice. IV. Identification and distribution in mouse spleen , 1975, The Journal of experimental medicine.

[49]  G. Roodman.  Novel targets for myeloma bone disease. , 2008, Expert opinion on therapeutic targets.

[50]  R. Steinman,et al.  Pillars Article: Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J. Exp. Med.1973. 137: 1142-1162. , 2007, Journal of immunology.

[51]  N. Munshi,et al.  Dysfunctional T regulatory cells in multiple myeloma. , 2006, Blood.

[52]  Yong‐jun Liu,et al.  IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. , 2005, Annual review of immunology.